These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 10571438

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Rotavirus vaccines and vaccination in Latin America.
    Linhares AC, Bresee JS.
    Rev Panam Salud Publica; 2000 Nov; 8(5):305-31. PubMed ID: 11190969
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis.
    Joensuu J, Koskenniemi E, Pang XL, Vesikari T.
    Lancet; 1997 Oct 25; 350(9086):1205-9. PubMed ID: 9652561
    [Abstract] [Full Text] [Related]

  • 5. Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children.
    Vesikari T, Karvonen AV, Majuri J, Zeng SQ, Pang XL, Kohberger R, Forrest BD, Hoshino Y, Chanock RM, Kapikian AZ.
    J Infect Dis; 2006 Aug 01; 194(3):370-6. PubMed ID: 16826486
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Immunogenicity, safety and protective efficacy of one dose of the rhesus rotavirus vaccine and serotype 1 and 2 human-rhesus rotavirus reassortants in children from Lima, Peru.
    Lanata CF, Black RE, Flores J, Lazo F, Butron B, Linares A, Huapaya A, Ventura G, Gil A, Kapikian AZ.
    Vaccine; 1996 Feb 01; 14(3):237-43. PubMed ID: 8920706
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines--report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group.
    Rennels MB, Glass RI, Dennehy PH, Bernstein DI, Pichichero ME, Zito ET, Mack ME, Davidson BL, Kapikian AZ.
    Pediatrics; 1996 Jan 01; 97(1):7-13. PubMed ID: 8545227
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Safety, immunogenicity, and protective efficacy of one and three doses of the tetravalent rhesus rotavirus vaccine in infants in Lima, Peru.
    Lanata CF, Midthun K, Black RE, Butron B, Huapaya A, Penny ME, Ventura G, Gil A, Jett-Goheen M, Davidson BL.
    J Infect Dis; 1996 Aug 01; 174(2):268-75. PubMed ID: 8699054
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Symptoms associated with rhesus-human reassortant rotavirus vaccine in infants.
    Joensuu J, Koskenniemi E, Vesikari T.
    Pediatr Infect Dis J; 1998 Apr 01; 17(4):334-40. PubMed ID: 9576390
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.